ATE514419T1 - Retardpräparat mit makroliden wie tacrolimus - Google Patents
Retardpräparat mit makroliden wie tacrolimusInfo
- Publication number
- ATE514419T1 ATE514419T1 AT10152774T AT10152774T ATE514419T1 AT E514419 T1 ATE514419 T1 AT E514419T1 AT 10152774 T AT10152774 T AT 10152774T AT 10152774 T AT10152774 T AT 10152774T AT E514419 T1 ATE514419 T1 AT E514419T1
- Authority
- AT
- Austria
- Prior art keywords
- macrolids
- tacrolimus
- sustained
- release preparation
- release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7903998 | 1998-03-26 | ||
JP18296398 | 1998-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE514419T1 true ATE514419T1 (de) | 2011-07-15 |
Family
ID=26420115
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99909332T ATE269075T1 (de) | 1998-03-26 | 1999-03-25 | Makrolid-formulierung mit verzögerter wirkstoffabgabe |
AT04002277T ATE464900T1 (de) | 1998-03-26 | 1999-03-25 | Retardpräparat mit makroliden wie tacrolimus |
AT10152774T ATE514419T1 (de) | 1998-03-26 | 1999-03-25 | Retardpräparat mit makroliden wie tacrolimus |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99909332T ATE269075T1 (de) | 1998-03-26 | 1999-03-25 | Makrolid-formulierung mit verzögerter wirkstoffabgabe |
AT04002277T ATE464900T1 (de) | 1998-03-26 | 1999-03-25 | Retardpräparat mit makroliden wie tacrolimus |
Country Status (32)
Country | Link |
---|---|
US (5) | US6440458B1 (de) |
EP (3) | EP1421939B9 (de) |
JP (4) | JP3714970B2 (de) |
KR (3) | KR100505464B1 (de) |
CN (1) | CN1229111C (de) |
AR (1) | AR023299A1 (de) |
AT (3) | ATE269075T1 (de) |
AU (1) | AU749623B2 (de) |
BR (1) | BRPI9909201B8 (de) |
CA (1) | CA2322516C (de) |
CZ (1) | CZ300548B6 (de) |
DE (2) | DE69918074T2 (de) |
DK (3) | DK2198858T3 (de) |
ES (3) | ES2219000T3 (de) |
HK (1) | HK1038185A1 (de) |
HR (1) | HRP20000707B1 (de) |
HU (1) | HU230889B1 (de) |
ID (1) | ID27825A (de) |
IL (1) | IL138466A (de) |
ME (2) | MEP30008A (de) |
NO (1) | NO330578B1 (de) |
NZ (1) | NZ507211A (de) |
PL (1) | PL193244B1 (de) |
PT (3) | PT1421939E (de) |
RS (1) | RS50164B (de) |
RU (1) | RU2214244C9 (de) |
SI (1) | SI1064942T1 (de) |
SK (1) | SK286887B6 (de) |
TR (1) | TR200002771T2 (de) |
TW (2) | TWI235068B (de) |
WO (1) | WO1999049863A1 (de) |
ZA (1) | ZA200004963B (de) |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030129215A1 (en) * | 1998-09-24 | 2003-07-10 | T-Ram, Inc. | Medical devices containing rapamycin analogs |
US7399480B2 (en) | 1997-09-26 | 2008-07-15 | Abbott Laboratories | Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices |
US6890546B2 (en) * | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
KR100505464B1 (ko) * | 1998-03-26 | 2005-08-04 | 후지사와 야꾸힝 고교 가부시키가이샤 | 서방성 제제 |
US7455853B2 (en) * | 1998-09-24 | 2008-11-25 | Abbott Cardiovascular Systems Inc. | Medical devices containing rapamycin analogs |
US6855172B2 (en) | 1998-10-13 | 2005-02-15 | Dry, Inc. | Dry-cleaning article, composition and methods |
US7807211B2 (en) | 1999-09-03 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of an implantable medical device |
US6790228B2 (en) | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US20070032853A1 (en) | 2002-03-27 | 2007-02-08 | Hossainy Syed F | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
HUP0204513A3 (en) * | 2000-03-08 | 2004-06-28 | Awd Pharma Gmbh & Co Kg | Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients |
DE60131399T3 (de) * | 2000-06-27 | 2019-11-14 | Vectura Ltd. | Herstellungsverfahren für partikel zur verwendung in einer arzneizusammensetzung |
EP2266549B1 (de) | 2000-06-27 | 2019-08-07 | Vectura Limited | Verfahren zur Herstellung von Partikeln zur Verwendung in einer pharmazeutischen Zusammensetzung |
US20040018228A1 (en) * | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
AU2002250968C1 (en) | 2001-02-19 | 2018-01-04 | Novartis Ag | Cancer treatment |
US6645946B1 (en) | 2001-03-27 | 2003-11-11 | Pro-Pharmaceuticals, Inc. | Delivery of a therapeutic agent in a formulation for reduced toxicity |
WO2002076474A1 (en) | 2001-03-27 | 2002-10-03 | Pro-Pharmaceuticals, Inc. | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
GB0108498D0 (en) * | 2001-04-04 | 2001-05-23 | Novartis Ag | Organic Compounds |
BR0209474A (pt) * | 2001-05-09 | 2006-02-07 | Novartis Ag | Métodos para imunomodulação seletiva |
AUPR529701A0 (en) * | 2001-05-28 | 2001-06-21 | Fujisawa Pharmaceutical Co., Ltd. | Pharmaceutical composition |
US20080145402A1 (en) * | 2001-09-10 | 2008-06-19 | Abbott Cardiovascular Systems Inc. | Medical Devices Containing Rapamycin Analogs |
GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
EP1443910A1 (de) * | 2001-11-02 | 2004-08-11 | Wockhardt Limited | Zubereitungen mit kontrollierter freigabe von makrolidantibiotika |
JP2003327536A (ja) * | 2002-03-07 | 2003-11-19 | Kitasato Inst:The | ヒト免疫不全症候群ウイルスの感染、増殖抑制剤 |
BR0314013A (pt) * | 2002-09-06 | 2005-07-12 | Abbott Lab | Equipamento médico contendo inibidor de hidratação |
EP1638549A4 (de) | 2003-03-10 | 2011-06-15 | Optimer Pharmaceuticals Inc | Neue antibakterielle mittel |
US20040185009A1 (en) * | 2003-03-19 | 2004-09-23 | Dexcel Pharma Technologies Ltd. | Composition and device for treating periodontal diseases |
GB0307866D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Pharmaceutical composition |
GB0307867D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Pharmaceutical composition |
US7476403B2 (en) * | 2003-06-16 | 2009-01-13 | Andrx Pharmaceuticals, Llc | Oral extended-release composition |
US20050118344A1 (en) | 2003-12-01 | 2005-06-02 | Pacetti Stephen D. | Temperature controlled crimping |
EP1641437A4 (de) * | 2003-07-09 | 2009-06-03 | Chong Kun Dang Pharm Corp | Feste dispersion von tacrolimus |
JP2007531697A (ja) * | 2003-07-11 | 2007-11-08 | プロ−ファーマシューティカルズ,インコーポレイティド | 疎水性薬剤のデリバリーのための組成物と方法 |
PT1663217E (pt) * | 2003-08-29 | 2010-10-18 | Lifecycle Pharma As | Dispersão sólida que compreende tacromílus |
PL1663217T3 (pl) * | 2003-08-29 | 2010-12-31 | Lifecycle Pharma As | Stałe dyspersje zawierające takrolimus |
US20050053664A1 (en) * | 2003-09-08 | 2005-03-10 | Eliezer Zomer | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
US20070122482A1 (en) * | 2003-10-03 | 2007-05-31 | Per Holm | Method for preparing modified release pharmaceutical compositions |
US7285544B2 (en) * | 2003-11-18 | 2007-10-23 | Bernstein Eric F | Use of nitroxides in treating skin disease |
WO2005063242A1 (en) * | 2003-12-30 | 2005-07-14 | Astellas Pharma Inc. | Use of macrolides for treating or preventing airflow obstruction |
KR100485877B1 (ko) * | 2003-12-30 | 2005-04-28 | 종근당바이오 주식회사 | 타크롤리무스를 생산하는 미생물 및 이를 이용한타크롤리무스의 대량 생산방법 |
WO2005079314A2 (en) * | 2004-02-13 | 2005-09-01 | Pro-Pharmaceuticals, Inc. | Compositions and methods used to treat acne and candida |
US20080286251A1 (en) * | 2004-08-02 | 2008-11-20 | Propharmaceuticals, Inc. | Compositions and Methods for the Enhancement of Chemotherapy with Microbial Cytotoxins |
WO2006021443A2 (en) * | 2004-08-26 | 2006-03-02 | Novartis Ag | Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator |
JP2008514706A (ja) * | 2004-09-29 | 2008-05-08 | コーディス・コーポレイション | 安定非晶質ラパマイシン様化合物の薬学的投与形態 |
EP1817314A1 (de) * | 2004-12-01 | 2007-08-15 | Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság | Nichthygroskopisches und pulverförmiges amorphes pimecrolimus |
CA2588480A1 (en) * | 2005-01-05 | 2006-08-10 | Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag | Amorphous tacrolimus and preparation thereof |
KR100678824B1 (ko) * | 2005-02-04 | 2007-02-05 | 한미약품 주식회사 | 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물 |
AU2006227623B2 (en) * | 2005-03-17 | 2011-10-20 | Elan Pharma International Limited | Injectable compositions of nanoparticulate immunosuppressive compounds |
WO2007083316A2 (en) * | 2006-01-23 | 2007-07-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Microspheres comprising nanocapsules containing a lipophilic drug |
HUP0600097A3 (en) * | 2006-02-08 | 2008-07-28 | Richter Gedeon Nyrt | Pharmaceutical compositions comprising tacrolimus and process for their preparation |
JP2007308479A (ja) | 2006-04-20 | 2007-11-29 | Shin Etsu Chem Co Ltd | 固体分散体製剤 |
US20080181947A1 (en) * | 2006-09-26 | 2008-07-31 | Astellas Pharma Inc. | Controlled release dosage form of tacrolimus |
EP1938804A1 (de) * | 2006-12-22 | 2008-07-02 | Novartis AG | Pharmazeutische Zubereitung enthaltend Neurokinin Antagonist |
CA2673959A1 (en) * | 2006-12-27 | 2008-07-10 | Astellas Pharma Inc. | Aminoalkyl methacrylate copolymer e for maintaining solubility of poorly-soluble drug |
US20090011018A1 (en) * | 2006-12-28 | 2009-01-08 | Astellas Pharma Inc., | Sustained release formulation for tacrolimus |
US7521523B2 (en) | 2006-12-28 | 2009-04-21 | Eastman Chemical Company | Oxygen-scavenging polyester compositions useful in packaging |
CA2673863A1 (en) * | 2006-12-28 | 2008-07-10 | Limerick Biopharma, Inc. | Methods and compositions for therapeutic treatment |
CA3027598C (en) | 2007-01-10 | 2020-07-21 | Board Of Regents The University Of Texas System | Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery |
US20100086592A1 (en) * | 2007-03-29 | 2010-04-08 | Panacea Biotec Limited. | Modified dosage forms of tacrolimus |
ITMI20070720A1 (it) * | 2007-04-06 | 2008-10-07 | Monteresearch Srl | Composizioni orali contenenti tacrolimus in forma amorfa |
US8703204B2 (en) | 2007-05-03 | 2014-04-22 | Bend Research, Inc. | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer |
US8309129B2 (en) | 2007-05-03 | 2012-11-13 | Bend Research, Inc. | Nanoparticles comprising a drug, ethylcellulose, and a bile salt |
PL2167033T4 (pl) | 2007-05-30 | 2018-08-31 | Veloxis Pharmaceuticals A/S | Podawana raz dziennie doustna postać dawkowania zawierająca takrolimus |
WO2008149230A2 (en) | 2007-06-04 | 2008-12-11 | Pfizer Products Inc. | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate |
US8974827B2 (en) | 2007-06-04 | 2015-03-10 | Bend Research, Inc. | Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer |
WO2009018338A2 (en) * | 2007-07-31 | 2009-02-05 | Limerick Biopharma, Inc. | Phosphorylated pyrone analogs and methods |
EP2601935A1 (de) | 2007-09-25 | 2013-06-12 | Solubest Ltd. | Zusammensetzungen mit lipophilen Wirkstoffen und Herstellungsverfahren dafür |
TW200932240A (en) | 2007-10-25 | 2009-08-01 | Astellas Pharma Inc | Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production |
AU2008316830B2 (en) | 2007-10-25 | 2016-03-17 | Cempra Pharmaceuticals, Inc. | Process for the preparation of macrolide antibacterial agents |
KR20090044269A (ko) * | 2007-10-31 | 2009-05-07 | (주)아모레퍼시픽 | 서방성 나노입자 및 이를 함유하는 화장료 조성물 |
US9724362B2 (en) | 2007-12-06 | 2017-08-08 | Bend Research, Inc. | Pharmaceutical compositions comprising nanoparticles and a resuspending material |
EP2240162A4 (de) | 2007-12-06 | 2013-10-09 | Bend Res Inc | Nanoteilchen mit einem nicht-ionisierbaren polymer und einem amin-funktionalisierten methacrylat-copolymer |
CL2008000374A1 (es) * | 2008-02-05 | 2008-04-04 | Igloo Zone Chile S A | Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve |
US8222272B2 (en) * | 2008-04-11 | 2012-07-17 | Roxane Laboratories, Inc. | Pharmaceutical formulation and process comprising a solid dispersion of macrolide (tacrolimus) |
WO2010004304A1 (en) * | 2008-06-17 | 2010-01-14 | Biotica Technology Limited | Novel compounds and methods for their production |
JP5602748B2 (ja) | 2008-10-24 | 2014-10-08 | センプラ ファーマシューティカルズ,インコーポレイテッド | トリアゾール含有マクロライドを用いた生体防御 |
EP3045043B1 (de) | 2009-02-26 | 2020-04-29 | Relmada Therapeutics, Inc. | Oral einnehmbare pharmazeutische zusammensetzungen aus 3-hydroxy-n-methylmorphinan mit verzögerter freisetzung und verwendungsverfahren dafür |
US9937194B1 (en) | 2009-06-12 | 2018-04-10 | Cempra Pharmaceuticals, Inc. | Compounds and methods for treating inflammatory diseases |
CN102724874B (zh) | 2009-09-10 | 2018-06-01 | 森普拉制药公司 | 治疗疟疾、结核病和mac疾病的方法 |
LT2575769T (lt) | 2010-02-17 | 2016-10-10 | Veloxis Pharmaceuticals A/S | Stabilizuota takrolimuzo kompozicija |
EP2541716A1 (de) | 2010-02-25 | 2013-01-02 | Panasonic Corporation | Bedarfs- und ausgabesteuerungsvorrichtung, bedarfs- und ausgabesteuerungsverfahren sowie programm dafür |
WO2012008159A1 (en) | 2010-07-14 | 2012-01-19 | Senju Pharmaceutical Co., Ltd. | Solid dispersion of alfa-ketoamide derivatives |
MA34586B1 (fr) * | 2010-08-25 | 2013-10-02 | Medis Lab | Particules cristallines de tacrolimus micronise a surface modifiee et compositions pharmaceutiques associees |
JP6042334B2 (ja) | 2010-09-10 | 2016-12-14 | センプラ ファーマシューティカルズ,インコーポレイテッド | 疾患治療のための水素結合形成フルオロケトライド |
US20140206717A1 (en) * | 2011-08-16 | 2014-07-24 | John Higgins | Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions |
KR101643219B1 (ko) * | 2011-10-06 | 2016-07-27 | 노파르티스 아게 | 40-o-(2-히드록시)에틸-라파마이신을 포함하는 제약 조성물 |
CA2868262A1 (en) | 2012-03-27 | 2013-10-03 | Cempra Pharmaceuticals, Inc. | Parenteral formulations for administering macrolide antibiotics |
JP6210983B2 (ja) * | 2012-07-06 | 2017-10-11 | 合同酒精株式会社 | 環状マクロライド系化合物の分離方法 |
EP2968801B1 (de) | 2013-03-14 | 2018-09-26 | Cempra Pharmaceuticals, Inc. | Verfahren zur behandlung von atemwegserkrankungen und formulierungen dafür |
EP2968384A4 (de) | 2013-03-15 | 2017-02-15 | Cempra Pharmaceuticals, Inc. | Konvergente verfahren zur herstellung antibakterieller makrolidmittel |
US9168246B2 (en) | 2013-06-27 | 2015-10-27 | Veloxis Pharmaceutical A/S | Regimen for suppressing organ rejection |
CN103432099A (zh) * | 2013-08-13 | 2013-12-11 | 江苏正大清江制药有限公司 | 一种他克莫司缓释胶囊及其制备方法 |
US20170072058A1 (en) | 2014-11-21 | 2017-03-16 | Solipharma Llc | Pharmaceutical composition containing tacrolimus and preparation methods thereof |
CN104473907A (zh) * | 2014-12-25 | 2015-04-01 | 北京华禧联合科技发展有限公司 | 一种他克莫司的口服缓释制剂 |
EP3297629A1 (de) | 2015-05-20 | 2018-03-28 | Novartis AG | Pharmazeutische kombination aus everolimus und dactolisib |
CN104840446B (zh) * | 2015-05-27 | 2017-08-11 | 福建科瑞药业有限公司 | 一种他克莫司药物组合物及其制备方法 |
KR102459684B1 (ko) | 2016-04-15 | 2022-10-26 | 바이오아트라, 인코퍼레이티드 | 항 Axl항체 및 이의 면역접합체와 이것들의 용도 |
US9956158B2 (en) * | 2016-09-08 | 2018-05-01 | Synergistic Therapeutics, Llc | Topical hair growth formulation |
BR112019010470A2 (pt) | 2016-11-23 | 2019-09-10 | Novartis Ag | métodos de realce de resposta imune com everolimo, dactolisib ou ambos |
WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
KR102081176B1 (ko) * | 2018-06-22 | 2020-02-25 | 주식회사 종근당 | 타크로리무스를 포함하는 서방형 약제학적 제제 |
US20220062305A1 (en) * | 2018-12-18 | 2022-03-03 | DDP Specialty Electronic Materials US, Inc. | Sustained release composition comprising an ethylcellulose |
GR1009790B (el) | 2019-03-20 | 2020-08-03 | Φαρματεν Α.Β.Ε.Ε. | Σκευασμα παρατεταμενης αποδεσμευσης που περιλαμβανει τακρολιμους |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL32929A (en) | 1968-09-03 | 1973-08-29 | Banker G | Controlled-release pharmaceutical compositions containing a polymer for chemisorbing the active drug |
US4127647A (en) | 1975-04-08 | 1978-11-28 | Meiji Seika Kaisha, Ltd. | Process for preparation of stable amorphous macrolide antibiotic solids |
US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
US4894366A (en) | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
JPS62208103A (ja) | 1986-03-07 | 1987-09-12 | Yokogawa Hewlett Packard Ltd | ロボツト運動制御システム |
GB8608080D0 (en) * | 1986-04-02 | 1986-05-08 | Fujisawa Pharmaceutical Co | Solid dispersion composition |
JPS63150220A (ja) * | 1986-12-15 | 1988-06-22 | Dainippon Pharmaceut Co Ltd | 経口用固形製剤の製造方法 |
US4968508A (en) | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
JP2822389B2 (ja) | 1987-06-05 | 1998-11-11 | 藤沢薬品工業株式会社 | 抗fr−900506物質抗体、および高感度酵素免疫測定法 |
EP0346427B1 (de) | 1987-12-09 | 1995-03-29 | FISONS plc | Makrozyklische verbindungen |
DE3742525C2 (de) | 1987-12-11 | 1998-02-19 | Hertz Inst Heinrich | Verfahren zur Herstellung von Metallalkylverbindungen und deren Verwendung |
FR2624732B1 (fr) | 1987-12-21 | 1991-02-15 | Synthelabo | Formulation pharmaceutique a liberation prolongee |
JPH02232814A (ja) | 1989-03-07 | 1990-09-14 | Fuji Photo Film Co Ltd | 磁気記録媒体 |
DK0406791T3 (da) | 1989-07-05 | 1995-03-27 | Fujisawa Pharmaceutical Co | Vandigt flydende præparat til ekstern anvendelse |
KR0159766B1 (ko) | 1989-10-16 | 1998-12-01 | 후지사와 토모키치로 | 양모제 조성물 |
NZ235991A (en) | 1989-11-09 | 1993-05-26 | Sandoz Ltd | Macrolide compounds and pharmaceutical compositions thereof |
JPH03232814A (ja) | 1990-02-08 | 1991-10-16 | Shin Etsu Chem Co Ltd | 徐放性錠剤の製造方法 |
JPH05505798A (ja) | 1990-03-13 | 1993-08-26 | フアイソンズ・ピーエルシー | 免疫抑制マクロ環状化合物 |
JPH05507915A (ja) | 1990-06-11 | 1993-11-11 | 藤沢薬品工業株式会社 | 特発性血小板減少性紫斑病およびバセドウ病治療薬製造のためのfk506等のマクロライド化合物の用途 |
US5643901A (en) | 1990-06-11 | 1997-07-01 | Fujisawa Pharmaceutical Co., Ltd. | Medicament for treating idiopathic thrombocytopenic purpura |
MY110418A (en) | 1990-07-02 | 1998-05-30 | Novartis Ag | Heteroatoms-containing tricyclic compounds. |
EP0480623A1 (de) | 1990-10-11 | 1992-04-15 | Merck & Co. Inc. | Halomakrolide und Derivate mit immunosuppressiver Wirkung |
US5247076A (en) | 1991-09-09 | 1993-09-21 | Merck & Co., Inc. | Imidazolidyl macrolides having immunosuppressive activity |
US5252732A (en) | 1991-09-09 | 1993-10-12 | Merck & Co., Inc. | D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity |
US5208241A (en) | 1991-09-09 | 1993-05-04 | Merck & Co., Inc. | N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity |
JP3128320B2 (ja) | 1992-03-28 | 2001-01-29 | 株式会社常盤電機 | 不燃性シート及びその製造方法 |
GB9208492D0 (en) * | 1992-04-16 | 1992-06-03 | Glaxo Spa | Heterocyclic compounds |
HUT66531A (en) | 1992-05-07 | 1994-12-28 | Sandoz Ag | Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them |
GB9209882D0 (en) * | 1992-05-07 | 1992-06-24 | Glaxo Lab Sa | Compositions |
JP2707023B2 (ja) * | 1992-07-01 | 1998-01-28 | 株式会社大塚製薬工場 | 経口吸収用製剤 |
GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
AU686115B2 (en) | 1992-11-02 | 1998-02-05 | Fujisawa Pharmaceutical Co., Ltd. | Imidazo (I,2-a) pyridine derivatives as bradykinin antagonists, pharmaceuticals and processes for their preparation |
ES2134860T3 (es) * | 1992-11-18 | 1999-10-16 | Fujisawa Pharmaceutical Co | Preparacion farmaceutica de accion prolongada. |
MY110603A (en) | 1993-05-27 | 1998-08-29 | Novartis Ag | Tetrahydropyran derivatives |
DE4329503A1 (de) | 1993-09-01 | 1995-03-02 | Galenik Labor Freiburg Gmbh | Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa |
US6204243B1 (en) | 1993-09-01 | 2001-03-20 | Novatis Ag | Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis |
JP3232814B2 (ja) | 1993-09-22 | 2001-11-26 | ジェイエスアール株式会社 | 感熱記録媒体用インキ組成物 |
CN1096862C (zh) * | 1994-05-06 | 2002-12-25 | 辉瑞大药厂 | 阿齐霉素的控释剂型 |
AR004480A1 (es) | 1995-04-06 | 1998-12-16 | Amico Derin C D | Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen |
FR2736550B1 (fr) * | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
CA2229718A1 (en) * | 1995-08-24 | 1997-03-06 | David J. Mathre | Process for the preparation of imidazolyl macrolide immunosuppressants |
US5705190A (en) * | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
TW426516B (en) | 1996-12-06 | 2001-03-21 | Fujisawa Pharmaceutical Co | An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds |
KR100505464B1 (ko) | 1998-03-26 | 2005-08-04 | 후지사와 야꾸힝 고교 가부시키가이샤 | 서방성 제제 |
-
1999
- 1999-03-25 KR KR10-2003-7005713A patent/KR100505464B1/ko not_active IP Right Cessation
- 1999-03-25 DK DK10152774.5T patent/DK2198858T3/da active
- 1999-03-25 ID IDW20002175A patent/ID27825A/id unknown
- 1999-03-25 TR TR2000/02771T patent/TR200002771T2/xx unknown
- 1999-03-25 PT PT04002277T patent/PT1421939E/pt unknown
- 1999-03-25 TW TW092115044A patent/TWI235068B/zh not_active IP Right Cessation
- 1999-03-25 ME MEP-300/08A patent/MEP30008A/xx unknown
- 1999-03-25 EP EP04002277A patent/EP1421939B9/de not_active Revoked
- 1999-03-25 US US09/403,787 patent/US6440458B1/en not_active Expired - Lifetime
- 1999-03-25 CN CNB998064157A patent/CN1229111C/zh not_active Expired - Lifetime
- 1999-03-25 RU RU2000126836A patent/RU2214244C9/ru active Protection Beyond IP Right Term
- 1999-03-25 KR KR10-2003-7016882A patent/KR100498765B1/ko not_active IP Right Cessation
- 1999-03-25 SI SI9930622T patent/SI1064942T1/xx unknown
- 1999-03-25 WO PCT/JP1999/001499 patent/WO1999049863A1/ja active IP Right Grant
- 1999-03-25 BR BRPI9909201A patent/BRPI9909201B8/pt not_active IP Right Cessation
- 1999-03-25 CA CA2322516A patent/CA2322516C/en not_active Expired - Lifetime
- 1999-03-25 SK SK1439-2000A patent/SK286887B6/sk not_active IP Right Cessation
- 1999-03-25 DE DE69918074T patent/DE69918074T2/de not_active Expired - Lifetime
- 1999-03-25 ES ES99909332T patent/ES2219000T3/es not_active Expired - Lifetime
- 1999-03-25 RS YUP-580/00A patent/RS50164B/sr unknown
- 1999-03-25 PL PL343096A patent/PL193244B1/pl unknown
- 1999-03-25 PT PT10152774T patent/PT2198858E/pt unknown
- 1999-03-25 ME MEP-2008-300A patent/ME00189B/me unknown
- 1999-03-25 EP EP10152774A patent/EP2198858B1/de not_active Expired - Lifetime
- 1999-03-25 AT AT99909332T patent/ATE269075T1/de active
- 1999-03-25 IL IL13846699A patent/IL138466A/xx not_active IP Right Cessation
- 1999-03-25 AT AT04002277T patent/ATE464900T1/de active
- 1999-03-25 EP EP99909332A patent/EP1064942B9/de not_active Expired - Lifetime
- 1999-03-25 ES ES04002277T patent/ES2343248T3/es not_active Expired - Lifetime
- 1999-03-25 ES ES10152774T patent/ES2367294T3/es not_active Expired - Lifetime
- 1999-03-25 TW TW088104712A patent/TW570814B/zh not_active IP Right Cessation
- 1999-03-25 KR KR10-2000-7010438A patent/KR100440553B1/ko active IP Right Grant
- 1999-03-25 HU HU0101237A patent/HU230889B1/hu unknown
- 1999-03-25 CZ CZ20003549A patent/CZ300548B6/cs not_active IP Right Cessation
- 1999-03-25 JP JP54564199A patent/JP3714970B2/ja not_active Expired - Lifetime
- 1999-03-25 NZ NZ507211A patent/NZ507211A/en not_active IP Right Cessation
- 1999-03-25 DK DK04002277.4T patent/DK1421939T5/da active
- 1999-03-25 PT PT99909332T patent/PT1064942E/pt unknown
- 1999-03-25 AT AT10152774T patent/ATE514419T1/de active
- 1999-03-25 AU AU28563/99A patent/AU749623B2/en not_active Expired
- 1999-03-25 DE DE69942286T patent/DE69942286D1/de not_active Expired - Lifetime
- 1999-03-25 DK DK99909332T patent/DK1064942T3/da active
- 1999-03-26 AR ARP990101353A patent/AR023299A1/es active IP Right Grant
-
2000
- 2000-09-18 ZA ZA200004963A patent/ZA200004963B/en unknown
- 2000-09-25 NO NO20004773A patent/NO330578B1/no not_active IP Right Cessation
- 2000-10-20 HR HR20000707A patent/HRP20000707B1/xx not_active IP Right Cessation
-
2001
- 2001-10-17 US US09/978,025 patent/US6576259B2/en not_active Expired - Lifetime
- 2001-12-14 HK HK01108795A patent/HK1038185A1/xx not_active IP Right Cessation
-
2003
- 2003-04-14 US US10/412,281 patent/US6884433B2/en not_active Expired - Lifetime
-
2004
- 2004-08-18 JP JP2004237946A patent/JP3992031B2/ja not_active Expired - Lifetime
- 2004-08-18 JP JP2004237947A patent/JP4622382B2/ja not_active Expired - Lifetime
-
2005
- 2005-02-17 US US11/059,439 patent/US20050169993A1/en not_active Abandoned
-
2008
- 2008-07-17 JP JP2008186587A patent/JP4992845B2/ja not_active Expired - Lifetime
- 2008-11-05 US US12/265,108 patent/US8551522B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE514419T1 (de) | Retardpräparat mit makroliden wie tacrolimus | |
ID30132A (id) | Turunan-turunan pirazol trisiklik | |
DE69827870D1 (de) | Drebohrmeissel mit beweglichen Formation-eingreifenden Elementen | |
DE50011454D1 (de) | Handgeschirrspülmittel mit mikrokapseln | |
NO20023149L (no) | Fenylpiperazinylderivater | |
NO993443D0 (no) | Kabinstruktur | |
DE60022833D1 (de) | Kugellager | |
DE69935070D1 (de) | Anzeigetafel | |
ATE213632T1 (de) | Fungizide zusammensetzung mit erhörter bioverfügbarkeit | |
DE69912059D1 (de) | Anzeigetafel | |
ID25567A (id) | Ulir-jepit dengan bahu-puntir | |
DE69934804D1 (de) | Supraleiter | |
DE29904983U1 (de) | Zusammensetzspiel | |
DE59911463D1 (de) | Fahrzeugleitvorrichtung mit Fahrstreckenabtastung | |
DE69934619D1 (de) | Veränderbarer Widerstand | |
MA26795A1 (fr) | Analgesiques tricycliques. | |
DE59911758D1 (de) | Würfel | |
DE29809177U1 (de) | Lichtdurchlässiges Bauelement | |
DE60029537D1 (de) | Variabler Widerstand | |
DE29813463U1 (de) | Ball | |
DE29805324U1 (de) | Dekorierbarer Spielball | |
DE29706817U1 (de) | Schwimmbekleidung | |
FR2784878B1 (fr) | Accoudoir | |
DE69919643D1 (de) | Elektrolumineszenzpaneel | |
DE29809174U1 (de) | Lichtdurchlässiges Bauelement |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 2198858 Country of ref document: EP |